Pharmaceutical - UK, Pharmaceutical

Filter

Current filters:

UKPharmaceutical

Popular Filters

1 to 25 of 274 results

UK's NICE recommends Selincro to help reduce alcohol dependence

UK's NICE recommends Selincro to help reduce alcohol dependence

26-11-2014

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Selincro (nalmefene)…

LundbeckNeurologicalPharmaceuticalRegulationSelincroUK

AstraZeneca’s Duaklir Genuair approved in the EU for COPD

AstraZeneca’s Duaklir Genuair approved in the EU for COPD

25-11-2014

The European Commission has granted marketing authorization for Anglo-Swedish pharma major AstraZeneca’s…

AstraZenecaDuaklir GenuairPharmaceuticalRegulationRespiratory and PulmonaryUK

Roche and Lundbeck at the Jefferies 2014 Global Healthcare Conference

Roche and Lundbeck at the Jefferies 2014 Global Healthcare Conference

24-11-2014

Pharma, biotech and health care companies convened in London last week to update investors at the Jefferies…

FinancialHealth Medical PharmaPharmaceuticalRocheUK

Highlights from the Jefferies 2014 Global Healthcare Conference

Highlights from the Jefferies 2014 Global Healthcare Conference

21-11-2014

Pharma, biotech and health care companies convened in London this week to update investors at the Jefferies…

ALK AbelloClinigen GroupCubistFinancialGW PharmaceuticalsPeter GeorgePharmaceuticalUK

Oncology specialists say UK's capacity crisis is impacting patient care

Oncology specialists say UK's capacity crisis is impacting patient care

21-11-2014

A survey carried out by Swiss drug major Roche has shown that frontline staff believe patient care is…

Markets & MarketingOncologyPharmaceuticalResearchRocheUK

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

UK diabetes patients being denied vital prescriptions for testing strips

19-11-2014

Patients in Britain with diabetes are missing out on vital prescriptions that let them keep tabs on their…

DiabetesHealthcarePharmaceuticalUK

Threat or promise by 2020? The FT Global Pharmaceutical and Biotechnology Conference 2014

Threat or promise by 2020? The FT Global Pharmaceutical and Biotechnology Conference 2014

19-11-2014

The Pharma Letter reports from the FT Global Pharmaceutical and Biotechnology Conference 2014.

FT Global PharmaceuticalMarkets & MarketingPharmaceuticalResearchUK

UK Patent Box changes require urgent clarification, says Withers & Rogers

19-11-2014

Last month, Treasury Minister David Gauke gave a robust defence of the UK's Patent Box scheme, which…

FinancialPatentsPharmaceuticalPoliticsUK

NICE seeks more information on Xolair to treat hives

19-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Swiss…

DermatologicalsNovartisPharmaceuticalPricingRegulationUKXolair

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

Trends for 2015 to be discussed at health care conference

Trends for 2015 to be discussed at health care conference

17-11-2014

Future trends for the health care industry were discussed in an Investing in Health care webinar this…

FinancialPharmaceuticalPharmaceuticals policyUK

ABPI speaks out against changes to UK Cancer Drugs Fund medicines list

ABPI speaks out against changes to UK Cancer Drugs Fund medicines list

14-11-2014

The Association of the British Pharmaceutical Industry has spoken out against imminent changes to how…

NHSOncologyPharmaceuticalRegulationUK

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

13-11-2014

The UK’s National Health Service has updated its procedure for evaluating drugs in the Cancer Drugs…

AvastinKadcylaOncologyPharmaceuticalRegulationSprycelUK

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

UPDATE: UK agrees “Patent Box” compromise with Germany

UPDATE: UK agrees “Patent Box” compromise with Germany

13-11-2014

Germany and the UK have agreed a joint proposal to advance the negotiations on new rules for preferential…

FinancialGermanyPatentsPharmaceuticalPoliticsUK

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

12-11-2014

The Health & Social Care Information Centre has published its report on the prescribing habits of the…

HumiraLucentisMarkets & MarketingNational Health ServicePharmaceuticalResearchUKUnited Kingdom

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

10-11-2014

The Scottish Medicines Consortium has approved two new treatments today, one for skin cancer and one…

Bristol-Myers SquibbDaklinzaNephrology and HepatologyOncologyPharmaceuticalRegulationUKYervoy

Scottish backing for Novartis’ Afinitor for kidney cancer patients

Scottish backing for Novartis’ Afinitor for kidney cancer patients

10-11-2014

The Scottish Medicines Consortium has issued a positive recommendation for Swiss pharma major Novartis’…

AfinitorClinical pharmacologyHealthHealth Medical PharmaNHSNovartisOncologyPharmaceuticalPricingRegulationUK

UK's NICE does not recommend Pfizer's Xiapex for Dupuytren's contracture

UK's NICE does not recommend Pfizer's Xiapex for Dupuytren's contracture

07-11-2014

The UK’s National Institute for Health and Care Excellence is consulting on provisional recommendations…

Anti-Arthritics/RheumaticsPfizerPharmaceuticalRegulationUKXiapex

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

04-11-2014

A new study has suggested that drugs currently being used to treat diabetes also have the potential to…

liraglutidelixisenatideNeurologicalNovo NordiskPharmaceuticalResearchSanofiUK

AstraZeneca and University of Glasgow partner to form immunology discovery center

AstraZeneca and University of Glasgow partner to form immunology discovery center

04-11-2014

The University of Glasgow and Anglo-Swedish drug major AstraZeneca have now officially launched the GLAZgo…

AstraZenecaImmunologicalsPharmaceuticalResearchUK

UK's NICE recommends GSK's Arzerra for untreated chronic lymphocytic leukemia

UK's NICE recommends GSK's Arzerra for untreated chronic lymphocytic leukemia

04-11-2014

The UK’s National Institute for Health and Care Excellence has issued new preliminary draft guidance…

ArzerraGSKOfatumumab InjectionOncologyPharmaceuticalRegulationUK

NICE recommends Pradaxa for DVT and PE

NICE recommends Pradaxa for DVT and PE

31-10-2014

In draft guidance published today, the UK health costs watchdog the National Institute for Health and…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

1 to 25 of 274 results

Parexel

Parexel

Back to top